Kezar Life Sciences, Inc. (KZR) Tops Q3 EPS by 4c

Kezar Life Sciences, Inc. (NASDAQ: KZR) reported Q3 EPS of ($0.32), $0.04 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $7 million versus the consensus estimate of $250 thousand.

For earnings history and earnings-related data on Kezar Life Sciences, Inc. (KZR) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• FedEx (FDX) PT Lowered to $424 at Bernstein SocGen Group
• Worried the AI trade has gone too far? Evercore likes these 4 stocks